For General Public

HIRANG Interns make up the leeway with a Local Pharmaceutical Company in Iloilo City for DOST-PNRI Hydrogels

The Department of Science and Technology – Philippine Nuclear Research Institute (DOST-PNRI) HIRANG Internship members, through the broad connection of their HIRANG mentor, Dr. Lawrence L. Ilag, PhD. JD., make up the leeway with a Local Pharmaceutical Company in Iloilo City that showed interest and willingness to adopt their Hydrogel technologies.  According to Mr. Gregory Ciocson, Head of the Business Development Section of PNRI, the local pharmaceutical company already signed a Non-Disclosure Agreement (NDA) with DOST-PNRI for their three (3) technologies as follows:

  1. Polyvinyl Pyrollidone Carrageenan Hydrogel Dressing
  2. Hemostat Dressing and Granules
  3. Crosslinking of CMHA by Gamma-Processing

A Non-Disclosure Agreement (NDA) states that the company signified its intent to adopt, utilize, make, produce, and/or commercialize the technology and/or the product using the technology.  By all means, it denotes confidentiality to all data and information on the methodology, processes, system, analyses, and papers involved in the technology and the use thereof, and any other data or information related thereto, in the intent of the company to utilize that technology, except those that are already part of the public domain.

Crosslinking of CMHA by Gamma-Processing technology is currently undergoing HIRANG Internship Program under the project, “Support to the Commercialization of 500 DOST-Generated Technologies and Strengthening the Country’s Intellectual Property and Technology Portfolios”. The CMHA technology is a technology which could help resolves problems related, but not limited, to ophthalmic injuries and defects, acute and chronic skin wounds, post-surgery treatments, urinary incontinence, dry eye symptoms, and pharmaceutical drug carrier.  DOST-PNRI Internship team members will provide the local pharmaceutical company a process flow of the product creation for them to scrutinize the logistics of the business.

After sealing the deal, the next phase to commercialization is the technology assessment phase. In this stage, the local pharmaceutical company will visit the facility and check the irradiation facility of DOST-PNRI. In their case, it is still not possible because of the current situation in the metro. Hence, Mr. Ciocson, one of the internship team members, is to draft a non-binding term sheet for the adaptor of the CMHA technology in case they want to deepen their relationship with them.